Kronos Bio Corporation (KRON) Price to Earnings Ratio

Kronos Bio Inc - graphic logo of issuer KRON

The market dynamics of Kronos Bio, Inc. (KRON) securities demonstrate the -0.80 indicator. Kronos Bio, Inc. (KRON) is developing a molecule discovery ecosystem via software that secures clinics through long-term B2B contracts. The business is currently revising its R&D expenditures and focusing on partner-led developments for leukemia therapy. Ownership of a unique platform for managing transcriptional networks allows the firm to claim pricing power during the commercialization of its drugs.

Kronos Bio Corp (KRON) - Price to Earnings Ratio from 07/04/2022 to 06/28/2025

Comprehensive metric breakdowns and analytics for Kronos Bio Corp (KRON)

- price and consensus price forecast:
Stock Price kronosbio.com|KRON - Price Target Chart
- market capitalization details:
Market Value Kronos Bio, Inc.|KRON - Real Price to Acquire Entire Company
- book capitalization information:
Accounting Value of a Share Kronos Bio|KRON - Company Book Value|Market-to-Book Ratio kronosbio.com|KRON - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Ratio Kronos Bio, Inc.|KRON - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Kronos Bio Corporation|KRON - Company Debts|Debts to Book Value Kronos Bio, Inc.|KRON - Company Long-Term Debt|Company Short-Term Debt Kronos Bio|Immediate Liquidity kronosbio.com
- earnings and valuation multiples indicators:
KRON - Net Profit|Projected Net Profit Kronos Bio, Inc.|KRON - Price to Earnings Ratio|Projected Price to Earnings Ratio Kronos Bio Inc|KRON - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Kronos Bio, Inc.|KRON - Operating profit before deduction of amortization|Earnings per share for the last four quarters Kronos Bio|KRON - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months kronosbio.com|KRON - Earnings growth in current year|Expected net earnings per share growth next year Kronos Bio, Inc.
Comprehensive company analysis:KRON (kronosbio.com)
Product sample of Kronos Bio, Inc.

Professional asset selection requires a rigorous analysis of market multiples. The P/E ratio correlates the current share price with net income, measuring the investment's payback period. For Kronos Bio, Inc. (KRON), this calculation reflects market confidence in the success of anti-tumor research supported by a stable raw material base. Optimizing compound supplies reduces operational risks, justifying potentially high growth expectations. By analyzing the current P/E valuation level, an investor determines a fair balance between price and future potential.

Analysis of competing companies

P/E Multiple incyte.com|Price to Earnings Ratio HUTCHMED (HCM)|Price to Earnings Ratio NUVB (Nuvation Bio Inc)|Day One Bio - Price to Earnings Ratio|Company Value to Net Income MNPR|INBX - Price to Earnings Ratio|Market Cap to Earnings I-Mab|Fennec Pharmaceuticals Inc. (FENC) - Price to Earnings Ratio|Price to Earnings Multiple HRTX|NVCT (Nuvectis) - P/E Multiple|Price to Earnings Ratio coherus.com (CHRS)|Price to Earnings Ratio Corbus Pharmaceuticals (CRBP)|CRDF - Market Cap to Earnings|Price to Earnings Ratio BeyondSpring BYSI|BioAtla Inc - Price to Earnings Ratio|LIXT - Price to Earnings Ratio|Market Cap to Earnings Citius Pharmaceuticals|CLRB: P/E Multiple|Market Cap to Net Income Ratio biolinerx.com BLRX|Price to Earnings Ratio CANF|Market Cap to Earnings Aprea APRE|Price to Earnings Ratio KZIA (Kazia Therapeutics)|SLXN (silexion.com) - Company Value to Net Income|NuCana - Price to Earnings Ratio|Market Price to Net Income Ratio CMRX (chimerix.com)|Cyclacel - P/E Multiple|Company Value to Net Income GTHX (G1 Therapeutics, Inc.)|KTRA: P/E Multiple|Market Cap to Earnings Oncternal Corp (ONCT)|Price to Earnings Ratio Portage Biotech Inc.